Clinical Trials

HCA Midwest Health currently has 19 clinical cancer trials available. Our clinical research program looks at new ways to prevent, detect, or treat disease.

Important Information


CDC guidance now recommends that moderately to severely immunocompromised patients receive an additional (third) dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna). If you have undergone anti-cancer therapy in the past year, you are within 1 year of stem cell transplantation or are receiving medications that suppress your immune system, you are encouraged to obtain a third COVID-19 vaccination shot. If you received the Johnson & Johnson single dose vaccination, please consult your doctor regarding next steps. Find vaccination locations here.

If you are within 100 days of a stem cell transplantation, we do not recommend that you receive a COVID-19 vaccination until you are cleared by your care team to do so. If you are currently on a clinical research trial, please contact your clinical research team for more guidance. Please contact your care coordinator if you have additional questions about receiving an additional COVID-19 vaccine shot.

The HCA Midwest Health clinical research program supports overall patient care by offering another therapeutic option through clinical trials. These clinical studies are available through Sarah Cannon Research Institute and various pharmaceutical and CRO partners.

AML 40: A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center


AML 52: Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine VS Venetoclax _ Aza in Newly Diagnosed AML Unfit for Intensive Chemo. PI: Suman Kambhampati, MD
Facility: Research Medical Center


LYM 120: Phase 2b Study of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Previously Treated DLBCL. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Research Medical Center, Menorah Medical Center


LYM 155: Phase 2 Study of Acalabrutinib as Post-AutoSCT Maintenance Therapy in Subjects with MCL. PI: Suman Kambhampati, MD.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


LYM 169: Phase 3 study of brentuximab vedotin/placebo + lenalidomide in R/R DLBCL. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


LYM 172: Phase 3, Study of R-CHOP Alone vs R-CHOP + Acalabrutinib as FL in Subjects ≤65 Years with Non-Germinal Center DLBCL, PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


MDS 26: Study of Magrolimab + Azacitidine vs Azacitidine + Placebo in Treatment-naïve Patients with Higher Risk MDS, PI: Suman Kambhampati, MD
Facility: Research Medical Center


MDS 27: Phase 3 Study of Venetoclax + Aza in Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS). PI: Suman Kambhampati, MD
Facility: Research Medical Center


MM 109: Study of Dara + Len vs. Lenalidomide Alone as Maint. in newly diagnosed Multiple Myeloma Who Are MRD + after Frontline AutoSCT. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


MM 123: Phase 3 Study of GSK2857916 + Pom. and Low-Dose Dex. vs Pom. + Bortezomib and Low Dose Dexa in R/R MM (DREAMM 8). PI: Suman Kambhampati, MD
Facility: Research Medical Center


MPN 11: Phase 3 Study of Navitoclax w/wo Ruxolitinib in Myelofibrosis and no prior treatment with JAK-2 inhibitor therapy (Transform-1)
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center


MPN 12: Phase 2 open-label study evaluating tolerability and efficacy of Navitoclax alone or in combination with ruxolitinib in subjects with myelofibrosis, PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

There are currently no research trials.

Catalyst:

Evaluates the safety and effectiveness of the Amulet LAA Occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. Principal Investigator: Dr. James Marcum


Facility: Overland Park Regional Medical Center, Research Medical Center


Champion AF:

To determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation. Principal Investigator: Dr. Dhanunjaya Lakkireddy


Facility: Overland Park Regional Medical Center, Research Medical Center


Define AF:

Aims to improve the understanding of how data from the Reveal LINQ™ or LINQ II™ insertable cardiac monitor (ICM) can be used to guide the management of Afib. Principal Investigator: Dr. Dhanunjaya Lakkireddy


Facility: Centerpoint, Research Medical Center, Overland Park Regional Medical Center, Menorah Medical Center


Leadless II:

Designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a single chamber pacemaker. Principle Investigator: Dr. Dhanunjaya Lakkireddy


Facility: Overland Park Regional Medical Center


LUX-Dx PERFORM:

To characterize the utilization of the remote programming feature of the Boston Scientific (BSC) Insertable Cardiac Monitor (ICM) device. The study will also collect data to characterize the performance of arrhythmia detection. Finally, data collected will be used to analyze and characterize the ICM system-related safety events. Principal Investigator: Dr. Scott Koerber


Facility: Centerpoint, Research Medical Center, Overland Park Regional Medical Center


RELIEVE-HF:

To provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System to improve clinical outcomes in a certain high-risk subset of symptomatic patients suffering from HF. Principal Investigator: Dr. Dhanunjaya Lakkireddy


Facility: Overland Park Regional Medical Center, Research Medical Center


Solve CRT:

To study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy. Principal Investigator: Dr. Dhanunjaya Lakkireddy


Facility: Overland Park Regional Medical Center, Research Medical Center

There are currently no research trials.

There are currently no research trials.

There are currently no research trials.

There are currently no research trials.

There are currently no research trials.

There are currently no research trials.

There are currently no research trials.